

Luxembourg, 30 November 2025

Environmental and Social Completion Sheet (ESCS)

Overview

Project Name:	Ferrer Pharmaceutical RDI III
Project Number:	2020-0577
Country:	Spain
Project Description:	The Project covers the promoter's R&D activities in a number of well-defined therapeutic areas. The promoter is an innovative pharmaceutical company which is also actively engaged in the response to COVID-19, working collaboratively across the research and healthcare communities to tackle the outbreak.

Summary of Environmental and Social Assessment at Completion

EIB notes the following Environmental and Social performance and key outcomes at Project Completion.

The Project was implemented in line with applicable EU Directives and EIB Environmental and Social Standards. All R&D activities were conducted within existing, authorised facilities, with no residual environmental impact. Ferrer maintained robust environmental management, evidenced by continued ISO 14001:2015 certification for its environmental management system, covering corporate services, pharmaceutical manufacturing, storage, distribution, and active pharmaceutical ingredient production across multiple Spanish sites.

All production and quality control activities in Ferrer's manufacturing sites are carried out under Good Manufacturing Practice (GMP) guidelines, or equivalent guidelines for non-medicinal products. Ferrer's sites located are routinely audited and inspected by EU and non-EU health authorities for GMP compliance.

No significant environmental impacts were identified during Project implementation. Ferrer proactively addressed regulatory requirements, such as the reformulation of Nadixa® to eliminate diethanolamine, and maintained high standards in clinical trial conduct, patient safety, and data integrity.

Ferrer's sustainability strategy prioritises environmental protection and climate action as core business objectives. The company's Climate Transition Plan sets out a clear pathway to achieve carbon positivity for direct emissions by 2030 and for all emissions by 2050. Key milestones include a 50% reduction in direct emissions and a 25% reduction in indirect emissions by 2030. The company's decarbonisation efforts are structured around operations, value chain, mobility, logistics, and climate culture, with significant investments in energy efficiency, renewable energy, and sustainable logistics.

Ferrer is recognised as the first Spanish pharmaceutical company – and the second worldwide – to achieve B Corp certification, reflecting its commitment to high standards of social and environmental performance.



Luxembourg, 30 November 2025

On the social front, the Project addressed areas of high unmet medical need, particularly in rare diseases, thereby improving access to innovative therapies for underserved patient populations and contributing positively to broader social outcomes.

Summary opinion of Environmental and Social aspects at completion:

EIB is of the opinion based on reports from the promoter and/or inputs provided by Lenders' Supervisors and others, where applicable, that the Project has been implemented in line with EIB Environmental and Social Standards, applicable at the time of appraisal.